Zinnate pills 125mg, 10pcs

Composition

1 tablet contains cefuroxime 250 mg;

excipients:

MCC,

croscarmellose sodium,

sodium lauryl sulfate,

hydrogenated vegetable oil,

colloidal silicon dioxide,

methyl hydroxypropyl cellulose,

propylene glycol,

methyl parahydroxybenzo-propyl parahydroxybenzoate,

opaspray is white.

Pharmacological action

Zinnat is a second-generation cephalosporin antibiotic for oral use. It acts bactericidal, disrupts the synthesis of the bacterial cell wall. It has a wide spectrum of action.

Resistant to most beta-lactamases.

Zinnat is highly active against aerobic gram-positive bacteria:  Staphylococcus aureus, Staphylococcus epidermidis (including penicillin-resistant strains and excluding rare methicillin-resistant strains), Streptococcus pyogenes, Streptococcus pneumoniae, Group B Streptococcus (Streptococcus agalactiae), Streptococcus mitis (viridans group), Bordetella pertusis; aerobic gram-negative bacteria:  Escherichia coli, Klebsiella spp., Proteus mirabilis, Providencia spp., Proteus rettgeri, Haemophilus influenzae (including ampicillin-resistant strains), Haemophilus parainfluenzae (including ampicillin-resistant strains), Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae (including strains containing penicillinase-producing and non-penicillinase-producing bacteria), Neisseria meningitidis, Salmonella spp. ; anaerobic gram-positive bacteria:  Peptococcus spp., Peptostreptococcus spp., Clostridium spp., Propionibacterium spp. ; anaerobic gram-negative bacteria:  Bacteroides spp, Fusobacterium spp. ; also active against Borrelia burgdorferi.

Cefuroxime is resistant to Clostridium difficile, Pseudomonas spp., Campylobacter spp., Acinetobacter calcoaceticus, Listeria monocytogenes, methicillin-resistant strains of Staphylococcus aureus, methicillin-resistant strains of Staphylococcus epidermidis, Legionella spp.

In vitro studies have shown that when cefuroxime is combined with antibiotics from the aminoglycoside group, an additive effect is observed, and in some cases – synergism.

Indications

Treatment of infectious and inflammatory diseases caused by drug-sensitive microorganisms:

• respiratory tract infections (including acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, postoperative infection of the chest);
• infections of ear, throat, nose (including sinusitis, tonsillitis, pharyngitis, acute otitis media);
• infections of the genitourinary system (including acute and chronic pyelonephritis, cystitis, urethritis and asymptomatic bacteriuria);
• infections of skin and soft tissue (including furunculosis, pyoderma, impetigo);
• gonorrhea (including acute uncomplicated gonococcal urethritis, and cervicitis);
• treatment of Lyme disease at an early stage and subsequent prevention of late manifestations in adults and children over 12 years.

Contraindications

Hypersensitivity to cephalosporin antibiotics.

Use with caution in the first trimester of pregnancy and lactation.

Side effects

From the digestive system:  nausea, vomiting, diarrhea; possible temporary increase in the activity of liver enzymes (ALT, AST, LDH), jaundice; cases of pseudomembranous colitis have been described.

From the hematopoietic system:  hemolytic anemia, eosinophilia, neutropenia, thrombocytopenia, leukopenia (sometimes pronounced). Allergic reactions:  skin rash, pruritus, urticaria, fever, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness; in isolated cases-anaphylaxis.

From the central nervous system:  headache.

Other services:  Coombs ‘ positive reaction.

Interaction

Concomitant use of cefuroxime and probenecid resulted in a 50% increase in cefuroxime AUC.

How to take, course of use and dosage

A single dose for adults and children over 12 years of age is usually 250 mg 2 times a day.

For severe infections of the lower respiratory tract-500 mg 2 times a day.

For urinary tract infections,125 mg is prescribed 2 times a day, for pyelonephritis-250 mg 2 times a day.

In the treatment of uncomplicated gonorrhea,1 g is prescribed once.

For Lyme disease – 500 mg 2 times a day for 20 days.

Special instructions

With prolonged use of Zinnat, increased growth of resistant microorganisms (Candida, Enterococci, Clostridium difficile) is possible, which may require discontinuation of treatment.

If diarrhea occurs during the use of antibiotics, including Zinnat, one should keep in mind the possibility of developing pseudomembranous colitis.

When treating Lyme disease with Zinnat, the Yarisch-Gersheimer reaction is sometimes noted.

This reaction is a direct consequence of the bactericidal action of Zinnat on the causative agent of the disease – the spirochete Borrelia burgdorferi.

Patients should be told that this is a frequent and common, spontaneous consequence of antibiotic treatment for Lyme disease.

Form of production

Film-coated tablets

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

3 years

Active ingredient

Cefuroxime

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

Children as prescribed by a doctor, Adults as prescribed by a doctor, Children over 12 years of age

Indications

Pharyngitis, Boils, Bronchitis, Urinary Tract Infections, Skin Infections, Respiratory Tract Infections, Pyoderma, Otitis Media, Urethritis, Sore Throat, Tonsillitis